ARKG
ยทCBOE
--
--(--)
--
--(--)
Key Stats
Assets Under Management
1.17BUSD
Fund Flows (1Y)
-75.64MUSD
Dividend Yield
--
Discount/Premium to NAV
-0.06%
Shares Outstanding
40.40M
Expense Ratio
0.75%
About ARK Genomic Revolution ETF
Issuer
ARK
Brand
ARK
Home Page
Inception Date
--
Structure
Open-Ended Fund
Index Tracked
--
Management Style
Active
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
ARK Investment Management LLC
Distributor
Foreside Fund Services LLC
ARKG reaches across multiple sectors and geographies for companies that the advisor believes will benefit from innovations in the genomics-related industry. Such companies are those that may develop, produce or enable targeted therapeutics, bioinformatics, stem cells or molecular diagnostics. The reality is almost all of its holdings are in US healthcare-related companies, with biotech naturally leading the way. This is a niche fund which employs an actively-managed strategy, hence investors should look closely at where the fund makes its bets before investing.
Classification
Asset Class
Equity
Category
Sector
Focus
Theme
Niche
Genomic Advancements
Strategy
Active
Geography
U.S.
Weighting Scheme
Proprietary
Selection Criteria
Proprietary
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | +9.77% | +6.02% | +23.67% | +27.41% | -2.17% | -68.79% |
NAV Total Return | +9.08% | +20.60% | +26.08% | +22.56% | +0.03% | -67.24% |
Ratings
No data is currently available
Ainvestโs AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investorsโtransforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Region

89.94%
10.06%
Category
Ratio
North America
89.94%
Europe
10.06%
Investment Style
Mega
Large
Medium
Multi
Small
Value
Blend
Growth
Multi-Cap Growth
Comprises companies of multiple sizes that have high growth potential. These ETFs focus on firms across different market caps with promising growth prospects.
Top 10 Holdings
Symbol
Ratio
TEM
Tempus AI
8.92%
CRSP
CRISPR Therapeutics
8.88%
TWST
Twist Bioscience
5.85%
GH
Guardant Health
5.59%
PSNL
Personalis
5.02%
BEAM
Beam Therapeutics
4.71%
RXRX
Recursion
4.62%
NTRA
Natera
4.60%
ILMN
Illumina
4.43%
TXG
10x Genomics
4.25%
Top 10 Weight 56.87%
35 Total Holdings
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2021-12-29 | 2021-12-30 | 2021-12-31 | 0.382 |
| 2020-12-29 | 2020-12-30 | 2020-12-31 | 0.791 |
Premium/Discount Chart
Premium/Discount to NAV
Price
1M
Assets Under Management
Assets Under Management
1M
Fund Flows
Inflows
Outflows
1M
